How we secured a COVID-19 convalescent plasma procurement scheme in Japan.
COVID-19
SARS-CoV-2
antibody
blood donation
convalescent plasma
plasmapheresis
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
16
05
2021
received:
11
02
2021
accepted:
17
05
2021
pubmed:
8
6
2021
medline:
3
8
2021
entrez:
7
6
2021
Statut:
ppublish
Résumé
In order to tackle the COVID-19 pandemic, a COVID-19 convalescent plasma (CCP) procurement program was initiated in Japan in April 2020. The program was a collaboration between a government-managed national hospital, an infectious disease research institute, and a blood banking organization. Each party assumed different responsibilities: recruitment, SARS-CoV-2 antibody profiling, and plasmapheresis; conduction of screening tests; and SARS-CoV-2 blood testing, respectively. We adopted a two-point screening approach before the collected CCP was labeled as a CCP product for investigational use, for which we mainly tested anti-SARS-CoV-2 antibody eligibility and blood product eligibility. Anti-SARS-CoV-2 spike protein titer was measured using enzyme-linked immunosorbent assay, and the IC As of September 17, 2020, our collection of CCP products was sufficient to treat more than 100 patients. As a result, projects for administration and distribution are also being conducted. We successfully implemented a CCP procurement scheme with the goal to expand to other parts of the country to improve treatment options for COVID-19.
Sections du résumé
BACKGROUND
In order to tackle the COVID-19 pandemic, a COVID-19 convalescent plasma (CCP) procurement program was initiated in Japan in April 2020. The program was a collaboration between a government-managed national hospital, an infectious disease research institute, and a blood banking organization. Each party assumed different responsibilities: recruitment, SARS-CoV-2 antibody profiling, and plasmapheresis; conduction of screening tests; and SARS-CoV-2 blood testing, respectively.
METHODS
We adopted a two-point screening approach before the collected CCP was labeled as a CCP product for investigational use, for which we mainly tested anti-SARS-CoV-2 antibody eligibility and blood product eligibility. Anti-SARS-CoV-2 spike protein titer was measured using enzyme-linked immunosorbent assay, and the IC
RESULTS
As of September 17, 2020, our collection of CCP products was sufficient to treat more than 100 patients. As a result, projects for administration and distribution are also being conducted.
CONCLUSIONS
We successfully implemented a CCP procurement scheme with the goal to expand to other parts of the country to improve treatment options for COVID-19.
Identifiants
pubmed: 34096059
doi: 10.1111/trf.16541
pmc: PMC8242376
doi:
Substances chimiques
Antibodies, Viral
0
Immune Sera
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1998-2007Subventions
Organisme : Health, Labor and Welfare Policy Research Grants for Research on Emerging and Re-emerging Infectious Diseases and Immunization
ID : 20HA1006
Organisme : Ministry of Health, Labour and Welfare, Japan
Informations de copyright
© 2021 AABB.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet Microbe. 2021 Jun;2(6):e240-e249
pubmed: 33778792
JAMA. 2020 Oct 6;324(13):1307-1316
pubmed: 32876695
Sci Rep. 2021 Mar 10;11(1):5563
pubmed: 33692457
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Transfus Apher Sci. 2020 Oct;59(5):102846
pubmed: 32593519
Blood Transfus. 2016 Mar;14(2):152-7
pubmed: 26674811
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Transfusion. 2020 Jul;60(7):1348-1355
pubmed: 32449169
Vox Sang. 2021 Jan;116(1):136-137
pubmed: 32324899
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Transfusion. 2021 Jul;61(7):1998-2007
pubmed: 34096059
Transfusion. 2020 Aug;60(8):1773-1777
pubmed: 32491199
Transfus Apher Sci. 2020 Oct;59(5):102877
pubmed: 32709475